Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERSEUS1: Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer
2017-000931-15Phase 2Unknown
- Sponsor
- The Institute of Cancer Research
- Start
- Jun 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in metastatic castration-resistant prostate cancer (mCRPC), sponsored by The Institute of Cancer Research. Primary endpoint: Composite tumour response by 24 weeks. Status: unknown.
02
Drugs
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2017-000931-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000931-15.